Abstract:
Immunotherapy has revolutionized the treatment of several cancers, including melanoma and lung cancer. However, for colorectal cancer, it is ineffective for 95% of patients with microsatellite-stable disease. Recent evidence suggests that the liver\'s immune microenvironment plays a pivotal role in limiting the effectiveness of immunotherapy. There is also evidence to show that targeting liver metastases with locoregional therapies, such as surgery or irradiation, could potentiate immunotherapy for these patients. This review presents evidence from preclinical studies regarding the underlying mechanisms and from clinical studies that support this approach. Furthermore, we outline potential directions for future clinical trials. This innovative strategy could potentially establish immunotherapy as an effective treatment for MS-stable colorectal cancer patients, which are currently considered resistant.
摘要:
免疫疗法彻底改变了几种癌症的治疗方法,包括黑色素瘤和肺癌.然而,对于结肠直肠癌,它对95%的微卫星稳定疾病患者无效。最近的证据表明,肝脏的免疫微环境在限制免疫治疗的有效性中起着关键作用。也有证据表明,局部治疗靶向肝转移,如手术或放射治疗,可以加强对这些患者的免疫治疗。这篇综述提供了有关潜在机制的临床前研究和支持这种方法的临床研究的证据。此外,我们概述了未来临床试验的潜在方向.这种创新策略可能会将免疫治疗作为MS稳定的结直肠癌患者的有效治疗方法。目前被认为是抗性的。